BamSEC and AlphaSense Join Forces
Learn More

Evoke Pharma Inc. – Material Contracts

Formerly NASDAQ: EVOK
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.9
from 8-K 9 pages Transition Services Agreement
12/34/56
EX-10.8
from 8-K 14 pages Transition Services Agreement
12/34/56
EX-10.7
from 8-K 14 pages Transition Services Agreement
12/34/56
EX-10.6
from 8-K 27 pages Second Amended and Restated Employment Agreement
12/34/56
EX-10.5
from 8-K 27 pages Second Amended and Restated Employment Agreement
12/34/56
EX-10.4
from 8-K 21 pages Third Amended and Restated Employment Agreement
12/34/56
EX-10.3
from 8-K 5 pages October 29, 2025 via Email Mr. Greg Skalicky, Chief Revenue Officer Eversana Life Science Services, LLC 190 N. Milwaukee Street Milwaukee, Wi 53202 Re: Letter Agreement Concerning Commercial Services Agreement Dear Greg
12/34/56
EX-10.2
from 8-K 14 pages Tender and Support Agreement
12/34/56
EX-10.1
from 8-K 14 pages Tender and Support Agreement
12/34/56
EX-10.1
from 10-Q 5 pages Evoke Pharma, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.4
from 10-Q 4 pages Seventh Amendment to Lease
12/34/56
EX-10.3
from 10-Q 16 pages Amended and Restated Employment Agreement
12/34/56
EX-10.2
from 10-Q 16 pages Amended and Restated Employment Agreement
12/34/56
EX-10.1
from 10-Q 16 pages Second Amended and Restated Employment Agreement
12/34/56
EX-10.1
from 8-K 4 pages Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, Ca 92075 Re: Warrant Amendments, Dated September 27, 2024, to Those Certain Series a Common Stock Purchase Warrants and Series C Common Stock Purchase Warrants
12/34/56
EX-10.1
from 8-K 2 pages Material contract
12/34/56
EX-10.11
from 10-K/A 57 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because Evoke Pharma, Inc. Has Determined the Information (I) Is Not Material and (II) Would Likely Cause Competitive Harm to Evoke Pharma, Inc. if Publicly Disclosed. Manufacturing Services Agreement 7 November 2017
12/34/56
EX-10.11
from 10-K 57 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because Evoke Pharma, Inc. Has Determined the Information (I) Is Not Material and (II) Would Likely Cause Competitive Harm to Evoke Pharma, Inc. if Publicly Disclosed. Manufacturing Services Agreement 7 November 2017
12/34/56
EX-10.1
from 10-Q 8 pages Sixth Amendment to Lease This Sixth Amendment to Lease (This “Amendment”) Is Made, for Reference Purposes Only, October 9, 2023 , by and Between Sb Corporate Centre III-IV, LLC, a Delaware Limited Liability Company (“Landlord”), and Evoke Pharma, Inc., a Delaware Corporation (“Tenant”), With Reference to the Following Facts
12/34/56
EX-10.1
from 10-Q 5 pages Evoke Pharma, Inc. Non-Employee Director Compensation Policy
12/34/56